Robeco Institutional Asset Management B.V. Sells 330,568 Shares of Danaher Corporation $DHR

Robeco Institutional Asset Management B.V. lowered its position in shares of Danaher Corporation (NYSE:DHR) by 79.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,148 shares of the conglomerate’s stock after selling 330,568 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Danaher were worth $18,643,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Prime Capital Investment Advisors LLC boosted its stake in shares of Danaher by 0.5% in the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock worth $2,039,000 after acquiring an additional 45 shares during the last quarter. Veery Capital LLC increased its position in shares of Danaher by 3.1% during the third quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after purchasing an additional 48 shares in the last quarter. Studio Investment Management LLC raised its stake in Danaher by 3.3% in the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after purchasing an additional 51 shares during the last quarter. OLD Second National Bank of Aurora raised its stake in Danaher by 0.5% in the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after purchasing an additional 57 shares during the last quarter. Finally, Adelphi Trust Co raised its stake in Danaher by 2.5% in the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock valued at $524,000 after purchasing an additional 57 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock opened at $230.36 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.25. The business has a 50 day simple moving average of $216.32 and a 200-day simple moving average of $197.35. The firm has a market capitalization of $161.94 billion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 2.87 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The firm had revenue of $6.55 billion during the quarter, compared to analysts’ expectations of $6.56 billion. During the same quarter last year, the firm earned $1.89 earnings per share. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. Equities research analysts anticipate that Danaher Corporation will post 8.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 26.19%.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Barclays raised their price objective on Danaher from $255.00 to $260.00 and gave the company an “overweight” rating in a report on Thursday. The Goldman Sachs Group reaffirmed a “buy” rating and set a $275.00 target price on shares of Danaher in a report on Thursday. Morgan Stanley increased their target price on shares of Danaher from $220.00 to $240.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Royal Bank Of Canada raised their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, October 5th. Finally, JPMorgan Chase & Co. raised their price target on shares of Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $242.91.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.